SAN DIEGO, Nov. 2, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced interim results from the ongoing open-label KINECT®-HD2 study about INGREZZA® (valbenazine) capsules ...
With a new FDA approval to rival Teva's Austedo, Neurocrine Biosciences’ Ingrezza is debuting in a treatment area with hundreds of millions of dollars of revenue potential. Late last week, the FDA ...
Motor symptoms of Huntington's disease (HD) are so central to the genetic neurodegenerative disease that it was long called Huntington's chorea. However, they're often untreated, despite a growing ...
Dyskinesia is when you experience involuntary movements. Chorea is one type of dyskinesia. It is associated with health conditions like Huntington’s disease, infection, or side effects of medications.
Chorea is a movement disorder that causes involuntary, unpredictable, and abrupt movements. There are two types of chorea: primary chorea and secondary chorea. According to a 2022 article, chorea is a ...
SAN DIEGO, Aug. 28, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data on now FDA-approved INGREZZA® (valbenazine) capsules for the treatment of adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results